(Image credit: Adobe Stock / ©Uladzislau)
Dry eye disease (DED) continues to grow in prevalence and complexity, challenging eye care practitioners to adopt new tools and evolving treatment methods. As we head into 2025, practitioners should consider the bigger picture when it comes to understanding the causes of dry eye and embrace a multifaceted approach to treatment to achieve better patient outcomes.
Dry eye does not exist in isolation. It is a multifactorial disease that can be influenced by dermatologic, anatomic, and aging-related factors. When we recognize this complexity, we can uncover underlying causes of dry eye in our patients that may otherwise go unnoticed and address them accordingly, providing more effective treatment.
Skin inflammation, particularly rosacea, frequently overlaps with DED, contributing to ocular surface inflammation and meibomian gland dysfunction (MGD). Several dermatologic conditions, including rosacea, blepharitis, atopic dermatitis (eczema), psoriasis, and even seborrheic dermatitis, can play a role, as they often affect the eyelids and surrounding skin, potentially disrupting the tear film production and leading to symptoms of dryness and irritation in the eyes.
On the anatomic front, there are numerous conditions that can set the stage for significant meibomian gland dropout, even in young adults. Some examples include sleep apnea, chronic allergic rhinitis, mouth breathing, nocturnal lagophthalmos, and incomplete blinking—conditions that expose the ocular surface and exacerbate tear evaporation.
Aging can also introduce challenges, such as changes in lid mechanics, facial volume loss, and reduced meibum production, which further contribute to dry eye symptoms. These issues are often compounded by medications used to treat various medical conditions that arise with age.
Practitioners must move beyond an eye-centered approach to dry eye management. By expanding your expertise to include an enhanced understanding of how dermatology, neurology, oculoplastics, otolaryngology, and autoimmune disorders can all play a role in contributing to DED, you elevate the level of care delivered to patients and help facilitate better outcomes.
Energy-based devices are revolutionizing how we treat dry eye. As prior authorization hurdles continue to rise, these in-office solutions will become an increasingly popular option for practitioners and patients:
Given the many co-conspirator conditions associated with dry eye, a multisystem, multitreatment approach is essential, and these modalities represent the future of comprehensive dry eye care.
The next generation of pharmacologic therapies promises more precise, mechanism-specific treatment options for DED. Moving beyond broad-spectrum anti-inflammatories, the latest advancements target specific pathways:
These emerging therapies show great potential and expand our treatment options to target specific inflammatory and neurosensory factors of dry eye. I hope to see these new options come to market later this year.
Dry eye management in 2025 will require eye care practitioners to think holistically, embrace advanced technologies, and stay informed about the latest therapies. As our options expand, it can feel overwhelming to determine the best way to incorporate them into our practices, but the key is to stay curious and keep learning.
To expand your knowledge, consider attending advanced courses at professional conferences, joining and engaging in practitioner-focused online discussion groups, and tracking innovations in dry eye through tools such as Google Scholar Alerts.
By taking a steady, deliberate approach to learning, adopting new tools, and understanding the mechanisms behind each treatment, we can become more effective in helping our patients combat dry eye and improve their daily lives.
Want more insights like this? Subscribe to Optometry Times and get clinical pearls and practice tips delivered straight to your inbox.